Global Atopic Dermatitis Market to Grow Slightly by 2022, Fuelled by New Product Launches
The atopic dermatitis therapeutic sales in the nine major markets (9MM) — the US, France Germany, Italy, Spain, UK, Japan, China and India — are forecast to increase from $3.9 billion in 2012 to $5.6 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 3.8%, says research and consulting firm GlobalData.
According to the company’s latest report*, the anticipated launch of new drugs by Sanofi/Regeneron and Anacor in the mid-term of the forecast period will bring a major boost to the market. Japan will also play a key role in driving global sales, while emerging markets India and China will experience rapid uptake of topical calcineurin inhibitors.
Tina Healy, GlobalData’s Director for Immunology, says: “Although both companies are expected to enter the atopic dermatitis space in 2016, Sanofi/Regeneron displays the greatest commercial prospects, as its pipeline candidate, dupilumab, is touted as a potential breakthrough therapy for moderate to severe disease. This stems from its potential to either compete with or displace gold-standard systemic agent cyclosporine. This in turn could address the high unmet need for an effective systemic drug for severe refractory disease.”
However, even though dupilumab is set to gain a foothold in the atopic dermatitis market by the late-forecast, it will not completely eradicate the high unmet need within the severe, recalcitrant group.
“The severe patient segment remains underserved as physicians have few to no pharmacological options following treatment failure with, or intolerability to, cyclosporine. As a result, physicians often resort to prescribing off-label therapies for these patients,” Healy says.
With an estimated drug-treated population that hovers around the 54 million mark during the next decade, opportunities will remain in this chronic dermatology disease for other drug developers with novel systemic therapies.
*PharmaPoint: Atopic Dermatitis — Global Drug Forecast and Market Analysis to 2022
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance